Pediatrix Medical Group, Inc.
- Open
- 26.07
- Day high
- 26.54
- Day low
- 25.33
- Prev close
- 26.61
- Volume
- 682K
- Mkt cap
- $2.1B
- P/E (TTM)
- 12.4
- EPS (TTM)
- $2.11
- P/B
- 2.4
- P/S
- 1.1
- Yield
- —
- Per share
- —
Pediatrix Medical Group, Inc. (MD) is a Healthcare company listed on NYSE. The stock is up 55% over the past year. Drillr has 1 published research article covering MD.
Pediatrix Medical Group, Inc. (MD) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 3 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
MD earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 4, 2026 | $0.59 | $0.63 | +6.6% | $488M | +1.9% |
| May 5, 2026 | $0.37 | $0.44 | +18.9% | $476M | +2.2% |
| Feb 19, 2026 | $0.53 | $0.50 | -5.7% | $494M | +5.2% |
| Feb 20, 2025 | $0.37 | $0.51 | +37.8% | $502M | +6.1% |
| Nov 1, 2024 | $0.37 | $0.44 | +18.9% | $511M | +4.9% |
| Feb 20, 2024 | $0.32 | $0.32 | -0.3% | $496M | -5.2% |
| Nov 2, 2023 | $0.43 | $0.32 | -25.2% | $507M | -0.2% |
| Aug 3, 2023 | $0.40 | $0.39 | -2.7% | $501M | +1.0% |
| May 2, 2023 | $0.22 | $0.23 | +3.6% | $491M | -0.0% |
| Feb 17, 2023 | $0.49 | $0.47 | -4.7% | $514M | +2.0% |
| Nov 3, 2022 | $0.55 | $0.40 | -27.5% | $490M | -4.5% |
| Aug 4, 2022 | $0.47 | $0.47 | -0.6% | $486M | -1.2% |
MD insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 14, 2026 | Linynsky Laura Adirector | Grant | 472 | $26.50 |
| Aug 14, 2026 | Starcher John M. Jr.director | Grant | 472 | $26.50 |
| Aug 14, 2026 | Weis Shirley Adirector | Grant | 472 | $26.50 |
| Aug 14, 2026 | Young Sylvia Jeandirector | Grant | 472 | $26.50 |
| Aug 14, 2026 | SANSONE GUY Pdirector | Grant | 472 | $26.50 |
| Aug 14, 2026 | Rucker Michael A.director | Grant | 472 | $26.50 |
| Aug 14, 2026 | Newman Kurt Douglasdirector | Grant | 472 | $26.50 |
| Aug 14, 2026 | McEachin Thomasdirector | Grant | 472 | $26.50 |
| Jun 24, 2026 | Haddock Davidofficer: EVP, GC & Corp Sec | Grant | 51,000 | — |
| Jun 24, 2026 | Haddock Davidofficer: EVP, GC & Corp Sec | Grant | 20,036 | — |
| May 14, 2026 | Weis Shirley Adirector | Sell | 36,028 | $23.75 |
| May 11, 2026 | Young Sylvia Jeandirector | Grant | 7,196 | — |
| May 11, 2026 | Linynsky Laura Adirector | Grant | 7,196 | — |
| May 11, 2026 | Starcher John M. Jr.director | Grant | 7,196 | — |
| May 11, 2026 | Weis Shirley Adirector | Grant | 7,196 | — |
Source: MD SEC Form 4 filings, latest Aug 14, 2026. For informational purposes only — not investment advice.
See the full MD insider & 13F page →Pediatrix Medical Group, Inc. company profile
Overview
Pediatrix Medical Group, Inc. (NYSE:MD) is a leading provider of specialized healthcare services for women, newborns, and children in the United States and Puerto Rico. Founded in 1979 and based in Sunrise, Florida, the company went public in 1995 and was formerly known as MEDNAX, Inc. before changing its name in July 2022 to better reflect its focus on pediatric and maternal care. The company operates a network of approximately 2,700 physicians and has undergone significant strategic restructuring in recent years, transitioning from a diversified healthcare services provider to a more focused organization concentrating on its core competencies in neonatal intensive care, maternal-fetal medicine, and pediatric subspecialty services.
Business
Pediatrix Medical Group operates in the specialized medical care sector, providing critical healthcare services primarily within hospital settings and select office-based locations. The company's services are organized around several key areas that address the most vulnerable patient populations - newborns, expectant mothers, and children with complex medical conditions. The company's neonatal care services represent its largest segment, providing specialized medical care to premature babies and newborns with complications in Neonatal Intensive Care Units (NICUs) across partner hospitals. These services are delivered by neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians who provide round-the-clock care for the most critically ill newborns. NICU care is essential because premature or medically complex newborns require specialized monitoring, respiratory support, nutritional management, and other intensive interventions that general pediatricians are not equipped to provide. Maternal-fetal medicine services constitute another major segment, offering both inpatient and office-based care to expectant mothers carrying high-risk pregnancies. This includes care for mothers with diabetes, hypertension, multiple pregnancies, or those carrying babies with detected abnormalities. The services are provided by maternal-fetal medicine subspecialists (also called perinatologists), obstetricians, maternal-fetal nurse practitioners, certified nurse midwives, ultrasonographers, and genetic counselors. These specialists use advanced diagnostic techniques like detailed ultrasounds and genetic testing to monitor and manage complex pregnancies. The company also provides pediatric cardiology services, offering both inpatient and office-based care for children with congenital heart defects and acquired heart disease. This includes specialized cardiac care for fetuses, newborns, children, and even adults with congenital heart conditions. Pediatric cardiologists perform procedures like echocardiograms, cardiac catheterizations, and provide ongoing management of complex heart conditions that require lifelong monitoring. Additionally, Pediatrix offers other pediatric subspecialty services through various specialists including pediatric intensivists (who care for critically ill children), pediatric hospitalists (who manage hospitalized children), pediatric surgeons, pediatric ophthalmologists, and pediatric ear, nose, and throat physicians. The company also provides support services in pediatric emergency rooms, labor and delivery areas, and nursery departments. Following its recent portfolio restructuring, approximately 80% of the company's revenue comes from hospital-based services, while 20% derives from office-based practices, primarily maternal-fetal medicine clinics.
Revenue model
Pediatrix Medical Group generates revenue primarily through professional medical service fees paid by insurance companies, government programs, and patients. The company's physicians and clinicians provide specialized medical services, and the company bills for these services using standard medical billing codes and fee schedules. The company's revenue streams include payments from commercial insurance plans, which typically provide higher reimbursement rates and represent the most profitable payer mix. Government programs like Medicaid and Medicare also constitute a significant portion of revenue, though at lower reimbursement rates. The company maintains high in-network status with payers (approximately 95%), which ensures more predictable reimbursement and reduces billing complications. For hospital-based services, Pediatrix often operates under professional services agreements with hospitals, where the company provides the specialized physicians and staff while the hospital provides the facilities and equipment. In some cases, hospitals may provide subsidies to help support these critical services, particularly in markets where the economics of specialized care might not otherwise be viable. These subsidies are a normal part of hospital partnerships and help ensure access to essential services like NICU care. The company's margins are influenced by several key factors. Payer mix significantly impacts profitability, with commercial insurance providing higher reimbursement than government programs. Patient acuity levels also affect revenue, as more complex cases typically generate higher billing. Physician recruitment and retention costs represent a major expense, as specialized physicians command high salaries and benefits. The company must also manage malpractice insurance costs, which are particularly high for high-risk specialties like neonatal care. Volume fluctuations can significantly impact revenue, as birth rates, NICU admissions, and high-risk pregnancies can vary based on demographic trends and economic conditions. Regulatory changes like the No Surprises Act have created additional administrative complexity and potential reimbursement challenges. The company has had to invest heavily in arbitration processes to maintain appropriate reimbursement levels when out-of-network billing occurs. Operational efficiency in revenue cycle management is crucial, as complex medical billing requires sophisticated systems and processes. The company has undergone significant transitions in its billing operations, moving to a hybrid model that combines internal capabilities with external vendor support to optimize collections and reduce administrative costs.
Competitive moat
Pediatrix Medical Group's competitive moat is moderately strong but faces several challenges. The company's primary competitive advantage lies in its specialized clinical expertise and established relationships with hospital systems. Neonatal intensive care, maternal-fetal medicine, and pediatric cardiology require highly specialized training that creates natural barriers to entry. These subspecialties typically require fellowship training beyond general pediatrics or obstetrics, creating a limited pool of qualified physicians. The company's hospital partnerships provide some defensive characteristics, as hospitals rely on Pediatrix to staff critical services that they cannot easily provide in-house. Switching costs for hospitals are relatively high because finding alternative providers of specialized neonatal or maternal-fetal care can be difficult, particularly in smaller markets. The company's scale allows it to maintain coverage across multiple hospitals and provide backup coverage when individual physicians are unavailable. However, the moat faces several vulnerabilities. Hospital systems are increasingly consolidating and some large health systems are bringing these services in-house, particularly in major metropolitan markets. This vertical integration trend poses a long-term threat to Pediatrix's business model. Additionally, reimbursement pressure from both government and commercial payers continues to intensify, potentially making some service lines economically unviable without hospital subsidies. The company's physician recruitment challenges also weaken its competitive position. Specialized physicians have multiple employment options, including direct hospital employment, academic medical centers, and private practice. Pediatrix must compete aggressively on compensation and lifestyle factors to attract and retain top talent. Regulatory and legal risks present ongoing challenges, particularly around billing practices and the No Surprises Act. The company's reliance on complex medical billing and occasional out-of-network situations creates potential for regulatory scrutiny and reimbursement disputes. The competitive landscape is fragmented, with both large competitors and smaller regional groups competing for hospital contracts. While Pediatrix's scale provides some advantages in terms of coverage and resources, it does not create an insurmountable barrier to competition. Overall, the company maintains a modest moat based on clinical specialization and hospital relationships, but this moat is under pressure from industry consolidation and reimbursement challenges.
Risks & safety
The company's margin of safety appears moderate to weak based on current financial metrics and operational challenges. • Cash and Liquidity: $99 million in cash and short-term investments as of Q1 2025, down significantly from $230 million in Q4 2024, indicating substantial cash consumption • Cash Flow Concerns: Negative $117 million operating cash flow and negative $121 million free cash flow in Q1 2025, representing a dramatic deterioration from positive $133 million operating cash flow in Q4 2024 • Debt Position: Net debt of approximately 1.7x EBITDA, which is manageable but concerning given the weak cash flow generation • Current Ratio: 1.81, indicating adequate short-term liquidity coverage • Valuation Metrics: Trading at 15x P/E ratio and 47x EV/EBITDA based on Q1 2025 results, suggesting expensive valuation relative to current earnings power • EBITDA Volatility: Significant fluctuation in EBITDA from negative $149 million in Q2 2024 to positive $50 million in Q4 2024, indicating operational instability • Revenue Decline: Q1 2025 consolidated revenue down 7% year-over-year despite same-unit growth, reflecting impact of portfolio restructuring • Other Considerations: Ongoing restructuring costs, RCM transition challenges, and physician recruitment pressures create additional operational risks
Recent development
Over the past few years, Pediatrix Medical Group has undergone a comprehensive strategic transformation focused on portfolio optimization and operational efficiency. The company initiated an accelerated portfolio restructuring plan beginning in 2023, systematically exiting underperforming office-based practices and concentrating resources on its core hospital-based services. This restructuring involved exiting businesses that generated approximately $200 million in annual revenue, including the complete exit from primary and urgent care clinic platforms. A major operational initiative has been the transition to a hybrid revenue cycle management (RCM) model. After experiencing significant challenges with its previous RCM vendor R1, the company partnered with Guidehouse to create a hybrid approach combining internal capabilities with external expertise. This transition, largely completed by Q3 2024, was designed to improve billing efficiency and collection rates while reducing administrative costs. The company has also focused heavily on strengthening hospital and health system relationships, recognizing these partnerships as critical to long-term success. Management has emphasized being the "employer of choice" for physicians and clinicians, investing in recruitment, retention, and development programs to address ongoing staffing challenges in specialized medical fields. Strategic acquisitions have emerged as a growth focus, with management indicating a favorable acquisition environment and actively pursuing opportunities to acquire NICU, maternal-fetal medicine, and obstetric hospital operations. The company views current market volatility as creating attractive acquisition opportunities. The corporate rebranding from MEDNAX to Pediatrix Medical Group in July 2022 symbolized the strategic shift toward focusing exclusively on women's and children's healthcare services, moving away from the previous diversified healthcare services model that included anesthesiology and other adult services. Throughout this transformation, the company has maintained its commitment to clinical research and education, continuing investments in programs that support evidence-based care and physician training, which helps differentiate its services and maintain clinical excellence standards.
MD company profile · for informational purposes only — not investment advice.
Track MD with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free